PALISADE BIO, INC. — Director's Dealing 2021

Apr 29, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: PALISADE BIO, INC. (PALI)
CIK: 0001357459
Period of Report: 2021-04-27

Reporting Person: Hallam Thomas (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-04-27	Common Stock	A	1592	—	Acquired	1592	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-04-27	Stock Option (Right to Buy)	$14.72	A	4078	Acquired	2022-10-10	Common Stock (4078)	Direct
2021-04-27	Stock Option (Right to Buy)	$18.39	A	27189	Acquired	2023-10-01	Common Stock (27189)	Direct
2021-04-27	Stock Option (Right to Buy)	$27.59	A	6797	Acquired	2025-02-02	Common Stock (6797)	Direct
2021-04-27	Stock Option (Right to Buy)	$27.59	A	477	Acquired	2024-02-02	Common Stock (477)	Direct
2021-04-27	Stock Option (Right to Buy)	$27.59	A	2719	Acquired	2027-11-10	Common Stock (2719)	Direct
2021-04-27	Stock Option (Right to Buy)	$27.59	A	95572	Acquired	2027-11-10	Common Stock (95572)	Direct
2021-04-27	Stock Option (Right to Buy)	$41.20	A	22730	Acquired	2029-03-22	Common Stock (22730)	Direct
2021-04-27	Stock Option (Right to Buy)	$41.20	A	8754	Acquired	2029-03-22	Common Stock (8754)	Direct
2021-04-27	Stock Option (Right to Buy)	$41.20	A	20392	Acquired	2029-03-22	Common Stock (20392)	Direct
2021-04-27	Stock Option (Right to Buy)	$53.33	A	15002	Acquired	2029-03-22	Common Stock (15002)	Direct
2021-04-27	Stock Option (Right to Buy)	$26.85	A	12294	Acquired	2030-02-19	Common Stock (12294)	Direct
2021-04-27	Stock Option (Right to Buy)	$17.72	A	27190	Acquired	2031-04-26	Common Stock (27190)	Direct

Footnotes

F1: The Reporting Person acquired the shares of the Issuer in exchange for 58,582 shares of common stock of Leading BioSciences, Inc. ("LBS"), pursuant to the Agreement and Plan of Merger, dated December 16, 2020, among Seneca Biopharma Inc., Townsgate Acquisition Sub 1, Inc. and LBS (the "Merger"). Per the terms of the Merger, each share of LBS's common stock was converted into the right to receive 0.02719 shares of Seneca's common stock. In the Merger, the name of the Issuer was changed from Seneca Biopharma, Inc. to Palisade Bio, Inc.

F2: The stock option vested according to the following schedule: 50% of the shares underlying the option vested on the grant date and the remaining 50% vested in six equal quarterly installments thereafter beginning on July 9, 2014.

F3: Received in the Merger in exchange for a stock option to acquire 150,000 shares of LBS common stock for $0.40 per share.

F4: The stock option vested according to the following schedule: 17% of the shares underlying the option vested on grant date and the remaining 83% vested in 10 equal quarterly installments thereafter beginning on June 30, 2014.

F5: Received in the Merger in exchange for a stock option to acquire 1,000,000 shares of LBS common stock for $0.50 per share.

F6: The option vests in 12 equal quarterly installments from the vesting commencement date.

F7: Received in the Merger in exchange for a stock option to acquire 250,000 shares of LBS common stock for $0.75 per share.

F8: The stock option is fully vested.

F9: Received in the Merger in exchange for a stock option to acquire 17,567 shares of LBS common stock for $0.75 per share.

F10: Received in the Merger in exchange for a stock option to acquire 100,000 shares of LBS common stock for $0.75 per share.

F11: The stock option vests according to the following schedule: 25% of the shares underlying the option vests on grant date and the remaining 75% vests in nine equal quarterly installments thereafter beginning on January 1, 2018.

F12: Received in the Merger in exchange for a stock option to acquire 3,515,000 shares of LBS common stock for $0.75 per share.

F13: The stock option vests according to the following schedule: 67% of the shares underlying the option vests on the grant date and the remaining 33% vests in eight equal quarterly installments thereafter beginning on March 31, 2019.

F14: Received in the Merger in exchange for a stock option to acquire 836,000 shares of LBS common stock for $1.12 per share.

F15: Received in the Merger in exchange for a stock option to acquire 322,000 shares of LBS common stock for $1.12 per share.

F16: Received in the Merger in exchange for a stock option to acquire 750,000 shares of LBS common stock for $1.12 per share.

F17: The stock option vests according to the following schedule: 67% of the shares underlying the option vests on the grant date and the remaining 33% vests in four equal quarterly installments thereafter beginning on March 31, 2019.

F18: Received in the Merger in exchange for a stock option to acquire 551,753 shares of LBS common stock for $1.45 per share.

F19: Received in the Merger in exchange for a stock option to acquire 452,200 shares of LBS common stock for $0.73 per share.

F20: Received in the Merger in exchange for a stock option to acquire 1,000,000 shares of LBS common stock for $0.48 per share.